Gilead Surges 9% as Wall Street Lifts Targets Across the Board

Gilead Sciences closed Thursday at $170.68, up 9.4% on the week, after a third-quarter earnings beat prompted one of the most unified rounds of analyst target upgrades the stock has seen in recent memory.

The catalyst was Wednesday's Q3 print. Gilead raised full-year revenue guidance to $30.0 to $30.4 billion, driven by continued strength in its HIV franchise. Biktarvy and Descovy both posted solid demand, and the company's year-to-date gain has now reached roughly 30%. The day-after move was 7.2%, the sharpest single-session reaction in at least the past two quarterly prints, the August result generated only a 1.7% move on the day.

The Street response was immediate and unusually coordinated. Ten firms raised their price targets on October 30 alone, all maintaining existing ratings, with no downgrades in the mix. JP Morgan's Chris Schott lifted his target from $170 to $190 while keeping Overweight. Morgan Stanley moved from $163 to $183. Wells Fargo went to $190 from $165. The highest target came from Scotiabank and Needham, both at $200. Even RBC, which holds the sole cautious Sector Perform rating, raised its target, from $126 to $131. The consensus mean price target now stands at $165.31, which sits below the current price of $170.68, reflecting how quickly the stock has moved through previously set levels. The Street is still catching up.

The bull case rests on the durability of the HIV franchise. Biktarvy retains 95% US coverage, and Gilead's FDA-accepted filing for an oral version of Yeztugo, targeting a February 2027 decision date, could extend its PrEP leadership well into the next decade. Oncology assets including Yescarta, Tecartus, and Trodelvy add diversification, and the cash flows from the HCV business remain intact. The more cautious view points to slower-than-expected Yeztugo uptake, weak PrEP persistence data, and limited evidence yet of meaningful script acceleration in oncology. Trodelvy's EVOKE-3 data disappointed, and the anito-cel program has not generated conviction. The two-sided debate is real, even if this week's price action went decisively one way.

Earnings-quality factor scores back the recent momentum. Gilead's EPS revision momentum ranks in the 93rd percentile on a 30-day basis and the 96th percentile on 90 days, placing it near the top of the universe on forward estimate upgrades. Earnings yield ranks in the 83rd percentile, and the dividend score hits 82, though the dividend history in the data does not reflect current payments. The short score of 32 is low and has barely moved all week, consistent with short interest at just 1.6% of free float, down 7.4% on the week. There is nothing in the lending market to complicate the picture: borrow availability is effectively unlimited, with cost to borrow running below 0.5%.

Options positioning is mildly elevated but not stretched. The put/call ratio at 0.63 is only half a standard deviation above its 20-day average of 0.61, well short of the 52-week high of 0.92. That is not the profile of a market bracing for a reversal. Among close peers, REGN gained 15.3% on the week, VRTX added 6.7%, and AMGN rose 6.1%, suggesting the large-cap biopharma move was broad, though Gilead's 9.4% sat toward the top of the group.

Institutional ownership is stable and concentrated in index and active managers. BlackRock added 2.8 million shares in the quarter to September 30, bringing its stake to 9.8%. T. Rowe Price added 3.8 million shares in the same period, the largest active addition among reported holders. On the insider side, all recent transactions were pre-planned sales under 10b5-1 arrangements, including a $1.77 million disposal by CEO Daniel O'Day on October 1. Planned sales carry less interpretive weight than discretionary ones, and the timing, before the earnings pop, makes them even less informative about conviction.

The next scheduled earnings event is November 6, one week away, which the data flags as the upcoming catalyst date.